Publicaciones recientes
Recent publications
__________________________________________________
Dr. Emilio Fernandez-Espejo et al.
A= artículo (article), R = revisión (review), F.I. = factor de impacto (SCI, impact
factor)
In English
Fernandez Espejo E. Pathogenesis of Parkinson's disease: prospects of
neuroprotective and restorative therapies. Molecular Neurobiology. 29: 1530, 2004. R. FI =
3.76
Fernandez-Espejo E, Rodriguez de Fonseca F., El Banoua
F, Caraballo I, Ferrer B,
Flores JA, Galan-Rodriguez B. Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are
improved by AM404, a modulator of endocannabinoid
function. Neuropsychopharmacology. 29: 1134-1142, 2004.
A. FI=5.88.
El Banoua
F, Caraballo I, Flores JA, Galan-Rodriguez B,
Fernandez-Espejo E. Effects on turning of
microinjections into basal ganglia of D1 and D2 dopamine receptors agonists,
and the cannabinoid CB1 antagonist SR141716A in a rat
Parkinson's model. Neurobiology of Disease.
16: 377-385, 2004. A. FI=4.12.
Fernandez-Espejo E, Galan-Rodriguez B. Sensorimotor
gating in mice is disrupted after AM404, an anandamide
reuptake and degradation inhibitor. Psychopharmacology.
175: 220-224, 2004. A.
FI = 3.62.
Flores JA, El Banoua F, Galán-Rodríguez B,
Fernandez-Espejo E. Opiate antinociception
is attenuated following lesion of large dopamine neurons of the periaqueductal grey: critical role for D1 (not D2) dopamine
receptors. Pain. 110: 214-223, 2004. A. FI = 4.83
Galan-Rodriguez B, Ramirez-Ponce P, El Banoua F, Flores JA, Bellido J,
Fernandez-Espejo E. Extra-adrenal chromaffin
cells of the Zuckerkandl’s paraganglion:
morphological and electrophysiological study. En: Cell Biology of the Chromaffin Cell (Borges R, Gandía
L, eds). Instituto Teófilo Hernando:
Madrid, pp. 275-279, 2004.
Fernandez-Espejo
E, Caraballo I, Rodriguez
de Fonseca F, El Banoua F, Ferrer B, Flores JA, Galan-Rodriguez
B. Cannabinoid CB1
antagonists possess antiparkinsonian efficacy only in
rats with very severe nigral lesion in experimental parkinsonism. Neurobiology of Disease. 18: 591-601, 2005. A. FI = 4.12
Fernandez-Espejo E, Armengol JA, Flores JA,
Galan-Rodriguez B, Ramiro S. Cells of the sympathoadrenal
lineage: biological properties as donor tissue for cell-replacement therapies
for Parkinson’s disease.
Brain Research Reviews.
49(2):343-354,
2005. CLAVE: R. FI = 5.59
Gorriti MA, Ferrer B, Del Arco I, Bermudez-Silva FJ,
de Diego Y, Fernandez-Espejo
E, Navarro M, Rodriguez de Fonseca F. Acute D9-tetrahydrocannabinol exposure facilitates quinpirole-induced hyperlocomotion.
Pharmacology,
Biochemistry and Behavior. 81: 71-77, 2005. FI = 2.09.
Flores JA, Galan-Rodríguez B, Ramiro S, Fernandez-Espejo E. Role for dopamine neurons of the rostral linear nucleus and periaqueductal grey in the rewarding and sensitizing properties of heroin. Neuropsychopharmacology. 31: 1475-1488, 2006. A. FI = 5.88
Brea J, Castro M, Loza MI, Masaguer CF, Raviña
E, Dezi C, Pastor M, Sanz F, Cabrero A, Galan-Rodriguez B, Fernandez-Espejo
E, Maldonado R, Robledo P. QF2004B, a
potential antipsychotic butyrophenone derivative with similar pharmacological properties to clozapine. Neuropharmacology. 51: 251-262, 2006. A. FI
= 3.86
Ferrer B, Gorriti MA, Palomino A, Gornemann I, De Diego Y, Bermúdez-Silva FJ,
Fernández-Espejo E, Moratalla R, Navarro M, Rodríguez
de Fonseca F. Cannabinoid CB1 receptor antagonism markedly
increases dopamine
receptor-mediated stereotypies.
European Journal of Pharmacology. 559: 180-183, 2007. A. FI
= 2.52
Fernández-Espejo E, Ramiro-Fuentes S, Portavella M.,
Moreno-Paublete R. Role for D-serine
within the ventral tegmental area in the development of
cocaine’s sensitization. Neuropsychopharmacology. 33:995-1003, 2008. A. FI= 5.889
Martín AB, Fernández-Espejo E, Ferrer
B, Gorriti MA, Bilbao A, Navarro M, Rodriguez de
Fonseca F, Moratalla
R. Expression and function of CB1 receptors in the rat striatum:
localization and effects on D1 and D2 dopamine
receptor-mediated motor behaviors. Neuropsychopharmacology. 33: 1667-1679, 2008. A. FI
= 5.889
Galán-Rodríguez B, Del Marco A,
Flores JA, Ramiro-Fuentes S,
González-Aparicio R, Túnez I, Tasset I, Fernández-Espejo E. Grafts of extra-adrenal chromaffin cells as
aggregates show better survival rate and regenerative effects on parkinsonian
rats than dispersed cells. Neurobiology of
Disease. 29: 529-542, 2008. A. FI = 4.128
Galán-Rodriguez
B, Suárez J, Gonzalez-Aparicio
R, Bermudez-Silva FJ,
Maldonado R, Robledo P, Rodriguez de Fonseca F, Fernandez-Espejo
E Oleoylethanolamide
exerts partial and dose-dependent neuroprotection
of substantia nigra dopamine neurons. Neuropharmacology 56: 653-664, 2009. A. FI = 3.215.
Fernández-Espejo
E. Pathogenesis of
oxidative stress and the destructive cycle in the substantia
nigra in Parkinson’s disease. In: Cortico-Subcortical
Dynamics in Parkinson’s Disease. Tseng, Kuei-Yuan (Ed.) Humana Press, 2009, 325 p. 76 illus. ISBN:
978-1-60327-251-3
Fernández-Espejo E., Liste
I. Cell-based replacement
therapies for Parkinson’s dissease. In: Cortico-Subcortical Dynamics in Parkinson’s Disease. Tseng, Kuei-Yuan
(Ed.) Humana Press, 2009, 325 p. 76 illus. ISBN: 978-1-60327-251-3.
Fernandez-Espejo E, Viveros M-P, Nuñez L, Ellenbroek B, Rodriguez de Fonseca F. Role of cannabis and endocannabinoids in the genesis of schizophrenia. Psychopharmacology. 206: 531-549, 2009. A
Fernandez-Espejo E, Ramiro-Fuentes S, Rodriguez
de Fonseca F. The absence of a functional PPAR-alpha gene in
mice enhances motor sensitizing effects of morphine, but not cocaine. Neuroscience. 164:
667–675, 2009. A.
Plaza-Zabala A, Berrendero F, Suarez
J, Bermudez-Silva
FJ, Fernandez-Espejo
E, Serrano A, Pavon FJ, Parsons
LH, Rodriguez de Fonseca F ,
Maldonado R, Robledo P. Effects of the
endogenous PPAR-α agonist, oleoylethanolamide
on MDMA-induced cognitive deficits in mice. Synapse. 64: 379-389, 2010. A
Flores JA, Galan-Rodriguez B, Rojo AI, Ramiro-Fuentes S, Cuadrado A, Fernandez-Espejo E Fibroblast growth factor-1 within the ventral tegmental area participates in motor sensitizing effects of morphine. Neuroscience. 165(1):198-211, 2010. A.
Ramiro-Fuentes S, Ortiz O, Moratalla R,
Fernandez-Espejo E. Intraaccumbal
rimonabant is rewarding but, in cocaine-treated rats,
produces aversion to the drug: critical role for glutamate receptors. Neuroscience. 167: 205–215, 2010. A.
Francina
Fonseca, Mònica Gratacòs, Geòrgia Escaramís, Rafael De Cid,
Rocío Martín-Santos, Emilio Fernández-Espejo, Xavier Estivill,
Marta Torrens. Response to methadone maintenance treatment is associated with MYOCD
and GRM6 genes. Molecular
Diagnosis and Therapy 14(3):171-178,
2010.
A.
Ramiro-Fuentes S, del-Marco A, Galan-Rodriguez B, Ramirez-Ponce
P, Fernandez-Espejo E. Morphophysiology of the Zuckerkandl’s
paraganglion: effects of dexamethasone
and aging. Neurobiology
of Aging. 31:
2115–2127, 2010. A.
Gonzalez-Aparicio R, Flores JA, Fernández-Espejo E. Antiparkinsonian trophic action of glial cell line-derived neurotrophic factor and transforming growth factor β1 is enhanced after co-infusion in rats. Experimental Neurology 226(1):136-147, 2010. A
Ramiro-Fuentes S, Fernandez-Espejo
E. Sensitization to cocaine is inhibited after intraaccumbal
GR103691 or rimonabant, but it is enhanced after coinfusion indicating functional interaction between accumbens D3 and CB1 receptors. Psychopharmacology. 214:949–959, 2011. A.
Gonzalez-Aparicio R, Flores JA, Tasset
I, Tunez I, Fernandez-Espejo
E. Mice lacking the peroxisome proliferator-activated receptor alpha-alpha gene present
reduced number of dopamine neurons in the substantia nigra without altering motor behavior or dopamine neuron
decline over life. Neuroscience. 186:161-169,
2011.
A.
Fernandez-Espejo E, Rodriguez-Espinosa
N. Psychostimulant drugs and Neuroplasticity. Pharmaceuticals
4: 976-991, 2011. A.
Fernández-Espejo
E. Exposure to Cry protoxins
induces oxidative stress, dopamine neuron death, and intraneuronal
a-synuclein-positive
inclusions in the substantia nigra
of rats. Journal of Neurodegeneration
and Regeneration. In press, 2011.
En español (Spanish)
Fernández Espejo E. ¿Es el fundus striati una nueva interfase límbico-motora?. Rev.
Neurol. (Barc) 30: 699,
2000. R. ISSN = 0210-0010
Fernández Espejo E. ¿Cómo
funciona el nucleus accumbens?. Rev.
Neurol. (Barc) 30: 845-849, 2000. R. ISSN = 0210-0010
Fernández Espejo E. Eficacia antiparkinsoniana de trasplantes de paraganglio
carotídeo y aórtico abdominal. Butlletí
de Transplantament (Barc) 15:
11-13. 2000.
Fernández
Espejo E. Bases neurobiológicas de la drogadicción. Rev. Neurol. (Barc). 34:659-665, 2002. R. ISSN = 0210-0010
Fernández
Espejo E., El Banoua F, Caraballo
I, Galan B, Flores JA. Trasplante de células
naturales "dopaminotróficas": nuevo
concepto terapéutico antiparkinsoniano. Rev. Neurol. (Barc). 36:540-544,
2002. R. ISSN = 0210-0010
Fernández Espejo E, Caille S, Stinus L. El sistema
endógeno de serotonina no participa en la abstinencia opiácea, aunque su
inhibición por estimulación del receptor 5-HT1A incrementa la eficacia antidisfórica de la clonidina en
ratas. Salud y Drogas. 3: 17-32, 2003. A.
Fernández
Espejo E. Neurobiología de la adicción a psicoestimulantes.
Rev.
Neurol. (Barc).
43: 147-154, 2006.
R. ISSN = 0210-0010
Fernández
Espejo E. Bases moleculares de la enfermedad de Parkinson. Mente y
Cerebro. 22: 81-87, 2007. R.
Fernández-Espejo
E, Galán-Rodríguez B. Neurofisiología de la acción psicotogénica del cannabis y cannabinoides.
En: Aspectos
psiquiátricos del consumo de cannabis: casos clínicos (Ramos JA, Arias F, Eds). Sociedad Española de Investigación en Cannabinoides, pp. 9-26, 2008. ISBN = 978-84-691-1315-8.
Fernández-Espejo E. Potencial de los
cannabinoides en el tratamiento de la enfermedad de
Parkinson. En: Actualización sobre el
potencial terapéutico de los cannabinoides (Ramos JA, Fernández-Ruiz J, Guzman M, Eds). Sociedad Española de Investigación sobre Cannabinoides, 2009, pp. 85-104. ISBN: 978-84-692-0828-1.
Guerri
C, Fernández Espejo E. Líneas maestras del futuro de la investigación en
trastornos adictivos. Redes.
15: 54-56, 2010. ISSN = 1699-2687